Diabetes affects approximately 387 million people worldwide. Diabetic retinopathy (DR) is the most common complication of diabetes and the major cause of vision loss in middle-aged subjects. The development of DR is strongly associated with the development of diabetic kidney disease, suggesting that the same pathogenic pathway underlies these complications. The renal renin-angiotensin system (RAS) is upregulated in diabetes, evidenced by increased tissue levels of angiotensin II, the main effector peptide of the RAS. Elevated levels of angiotensin II contribute to pathogenic processes, such as inflammation, vascular remodeling, and oxidative stress, that are associated with various renal and cardiovascular disorders, like heart failure, hypertension, diabetes, and other metabolic disorders. Diabetic retinopathy is associated with activation of the local RAS in the eye, evidenced by an increase in retinal angiotensin II levels. Blocks of the RAS, like angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARBs) provide protection against the progression of cardiovascular disorders, diabetic kidney disease, and diabetic retinopathy. Still, these drugs are unable to completely reverse or halt the progression of these complications. The natriuretic peptide system (RAS) contributes to pathogenesis of diabetic retinopathy (DR). Yet RAS blockers have only limited beneficial effects on progression of DR in clinical trials. The natriuretic peptide system offsets RAS, so that enhancing the activity of this system on top of RAS blockade might be beneficial. Neprilysin has an important role in the degradation of natriuretic peptides. Therefore, we hypothesize that dual angiotensin receptor-neprilysin inhibition (ARNI) may outperform angiotensin receptor blocker (ARB) in protection against DR. We tested this hypothesis in streptozotocin-induced diabetic transgenic (mRen2)27 rats. Beneficial effects of combined AT1 receptor/neprilysin inhibition (ARNI) versus AT1 receptor blockade alone in the diabetic eye. Investigative Ophthalmology & Visual Science. 2016;57:6722-6730. DOI:10.1167/iovs.16-20289

Dysfunction of the renin-angiotensin system (RAS) contributes to pathogenesis of diabetes and diabetic retinopathy (DR). The AT1 receptor blocker, irbesartan, neprilysin, thiorphan (ARNI) occurs during the final 3 weeks. Neprilysin and capillary loss were evaluated. Real-time polymerase chain reaction (RT-PCR) analyses were performed to quantify the retinal level of inflammatory cell markers. Both ARB- and ARNI-treated groups showed similarly reduced retinal apoptotic cell death, gliosis, and capillary loss compared to the vehicular-treated group in the 5-week study. Treatment with ARNI reduced the expression of inflammatory markers more than ARB treatment in the 5-week study. In the 12-week study, ARNI treatment showed significantly more reduction in apoptotic cell death (51% vs. 25% reduction) and capillary loss (68% vs. 43% reduction) than ARB treatment. Treatment with ARNI provides better protection against DR in diabetic (mRen2)27 transgenic rats, compared to ARB alone. This approach may be a promising treatment option for patients with DR.

Keywords: diabetes, diabetic retinopathy, renin-angiotensin system, AT1 receptor, angiotensin receptor blocker, irbesartan, neprilysin, thiorphan
alone. This effect may even be independent of blood pressure. These results suggest dual inhibition may provide better protection against DR, compared to ARB alone. We tested this hypothesis in transgenic (mRen2)27 (Ren2) rats made diabetic with streptozotocin (STZ) injection, and thereafter once weekly or every other week (i.e., during weeks 2–5 or 9–12) with vehicle (saline containing 0.2% dimethylsulfoxide [DMSO]). Rats in the 5- and 12-week groups, respectively; Precision Xceed; Abbott, Chicago, IL, USA) were used as wild-type controls. Eyes were harvested at the end of the 5-week or 12-week study, one eye from each animal was fixed in 4% paraformaldehyde (PFA) for histologic analysis and the other eye was snap frozen in liquid nitrogen for protein and gene expression analysis.

**NEP Activity Assay**

Frozen eyes from each experimental group were dissected to isolate retinal tissue that then were homogenized by sonication in NEP assay buffer (100 mM Tris-HCl pH 7.5, 50 mM NaCl, 10 μM ZnCl2). Neprilysin activity assay was performed using 5 μg of retinal protein in black 96-well opaque plates with the fluorogenic peptide substrate Mca-RPPGFSAFK(Dnp)-OH (Enzo Life Science, Farmingdale, NY, USA) added at a final concentration of 20 μM. The enzymatic reaction was done at 37°C in the presence and absence of the NEP inhibitor thiorphan at 2 μM concentration. The enzymatic reaction was recorded in a SpectraMax M3 fluorescence microplate reader (Molecular Devices, Sunnyvale, CA, USA) for 1 hour with excitation at 320 nm and emission at 405 nm as described previously. All measurements were performed in duplicate and the data represent the means of three assay results.

**Immunofluorescence**

Eyes fixed in 4% PFA were processed for paraffin embedding. Paraffin sections (4 μm thick) were cut and mounted on superfrost slides. Sections were deparaffinized in xylene and decreasing concentration of alcohol. This was followed by antigen retrieval step where the slides were boiled for 20 minutes in sodium citrate buffer, pH 6.0. The sections then were incubated in blocking solution (5% BSA + 0.3% Triton X-100 in PBS) for 1 hour at RT. Sections were washed in PBS containing the nuclear counterstain DAPI (4',6-diamidino-2-phenylindole), and mounted in Dako mounting media (DAKO). For TUNEL staining the In Situ Cell Death Detection Kit, TMR red (Roche Applied Science, Indianapolis, IN, USA) was used on paraffin sections in accordance with the manufacturer’s instructions. The images were captured on a Keyence confocal microscope (KEYENCE Corporation, Itasca, IL, USA) for quantitative analysis of retinal damage.

**Methods**

**Animal Studies**

Heterozygous male Ren2 rats (age 10 weeks, weight 300–500 g) were obtained by crossing homozygous Ren2 and Sprague-Dawley (SD) rats. Only male Ren2 rats were used for this particular study as the females of this transgenic model develop a much milder phenotype. Studies were performed in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and under the regulation and permission of the Erasmus MC Animal Care Committee. Diabetes mellitus was induced by administering streptozotocin (55 mg/kg intraperitoneal [IP]; Merck Millipore, Amsterdam, The Netherlands), and diabetic animals were studied for 5 or 12 weeks. In the 5-week group, heart rate and BP were measured by radiotelemetry transmitters, implanted 2 weeks before induction of diabetes. Rats were checked daily for nonfasting blood glucose and β-ketone levels until day 3 after STZ injection, and thereafter once weekly or every other week (5- and 12-week groups, respectively; Precision Xceed; Abbott, Zwolle, The Netherlands). Only rats with γ-glucose >15 mmol/L were considered diabetic; they received 2 to 4 U insulin per day (Levemir; Novo Nordisk, Bagsvaerd, Denmark). Rats in both groups were treated during the final 3 weeks of the study (i.e., during weeks 2–5 or 9–12) with vehicle (saline containing 0.2% dimethylsulfoxide [DMSO]), the ARB irbesartan (15 mg/kg/day; Sanofi-Aventis, Chilly-Mazarin, France), or the ARNI irbesartan-thiorphan (0.1 mg/kg/day diluted in DMSO; Sigma-Aldrich Corp., St. Louis, MO, USA) making use of osmotic minipumps (2ML4; ALZET, Cupertino, CA, USA). After 3 weeks of treatment, animals were killed by IP pentobarbital injection (200–240 mg/kg). Renal, cardiac, and vascular data on these animals have been reported previously. Each experimental group had 7 to 12 rats. In addition, eyes also were obtained from 8 age-matched untreated nondiabetic Sprague-Dawley rats that were used as wild-type controls. Eyes were harvested at the end of the 5-week or 12-week study, one eye from each animal was fixed in 4% paraformaldehyde (PFA) for histologic analysis and the other eye was snap frozen in liquid nitrogen for protein and gene expression analysis.

**Table 1.** Real-Time PCR Primers

| Gene      | Accession Number | Sequences            |
|-----------|------------------|----------------------|
| ICAM-1    | NM_012967        | 5'CCCCACCTACATACTTCTTCACC'T 5'  |
| TNF-α     | NM_012675        | CTTATCTACTCCAGGTTCCTTC                  |
| VEGF      | NM_031836        | TGCACCACGACAGAGGCAAGAGAAGCT            |
| MCP-1     | NM_031550        | GCAGCAGGTGCTCCAAAAAGAGCT             |

**Table 2.** Main Characteristics of DM Ren2 Rats That Were Treated for 5 Weeks With Vehicle, ARB or ARNI

| Parameter                          | 5 Wks. DM | 12 Wks. DM |
|------------------------------------|-----------|------------|
| **Vehicle**                        | ARB       | ARNI       | ARB       | ARNI       |
| Body weight, g                     | 448 ± 13  | 452 ± 16   | 450 ± 11  | 448 ± 9    |
| Blood glucose, mmol/L              | 27 ± 0.6  | 27 ± 0.7   | 27 ± 0.5  | 27 ± 0.3   |
| Baseline mean arterial pressure, mm Hg | 157 ± 10  | 160 ± 10   | 154 ± 10  | 25 ± 1.9   |
| Change in mean arterial pressure, mm Hg | -9.5 ± 4.3 | -45.0 ± 7.8†| -47.7 ± 7.9†| 26 ± 0.7   |

Treatment was started either 2 weeks (“5 weeks DM”) or 9 weeks (“12 weeks DM”) after the induction of DM. Data are mean + SEM of 7 to 12 rats.

* P < 0.05 versus baseline.
† P < 0.05 versus vehicle.
IL, USA) or on a spinning disc confocal microscope (Ultra VIEW Vox; PerkinElmer, Waltham, MA, USA) using a ×20, ×40, and/or ×60 objective lens and were prepared for presentation using Adobe Photoshop (Adobe Systems, Inc., San Jose, CA, USA). For GFAP quantification, digital images captured in Adobe Photoshop were adjusted similarly for brightness and contrast. Images were thresholded in ImageJ (National Institutes of Health [NIH], Bethesda, MD, USA) and the fluorescence intensity and area were quantified using its Measure module. For cell counts and GFAP expression, each quantification was performed on at least 5 sections from at least 6 animals (i.e., at least 30 sections each experimental group).

Western Blot Analysis

To quantify the level of GFAP expression in the different experimental groups, retinal tissues were collected in cold RIPA buffer (Sigma-Aldrich Corp.) supplemented with protease inhibitors and were homogenized by sonication. Homogenized tissues were centrifuged at 12,000g for 15 minutes at 4°C and the supernatant was collected. The protein concentration was detected by Bio-Rad Protein Assay kit (Bio-Rad Life Sciences, Hercules, CA, USA). Protein samples (20 μg) were loaded and separated on 10% gels for 1 hour at 120 V in Tris-glycine buffer and electrophoretically transferred onto polyvinylidene fluoride membrane. Immunodetection was performed on blots blocked in fluorescence-blocking buffer for 1 hour (Rockland Immunochemicals, Inc., Gilbertsville, PA, USA) and then incubated with primary (rabbit anti- GFAP; 1:2000; Sigma-Aldrich Corp.), and secondary (goat anti-rabbit IR Dye 800; Rockland Immunochemicals, Inc.) antibodies. β-Actin antibody (mouse anti-β-actin; 1:5000; Sigma-Aldrich Corp.) immunoblotting was used as a loading control. Immunoblots were visualized and quantified by using a Li-Cor odyssey infrared imager after normalizing it to β-Actin (Odyssey; Li-Cor, Lincoln, NE, USA).

Trypsin Digest Preparations of Retinal Vasculature

Trypsin digest preparations of retinal vasculature were made as described previously.29 Briefly, the retinas were dissected from the 4% PFA fixed eye cups, washed in water for an hour, and digested in 3% trypsin for 2 to 3 hours at RT. The tissue then was transferred into water and the network of vessels was freed from adherent retinal tissue by gentle shaking and manipulation under a dissection microscope. The vessels then were mounted on clean slides and allowed to dry and stained with periodic acid Schiff-hematoxylin and eosin (PAS-H&E; Gill No.3; Sigma-Aldrich Corp.) following manufacturer’s instructions. Real-time PCR

Real-Time PCR Analysis

Total RNA was isolated from frozen rat retinal samples using Trizol Reagent (Invitrogen, Carlsbad, CA, USA) according to manufacturer’s instruction. Reverse transcription was performed using Enhanced Avian HS RFP PCR kit (Sigma-Aldrich Corp.) following manufacturer’s instructions. Real-time PCR

RESULTS

Induction of Diabetes Mellitus and General Physiologic Characteristics

Ren2 rats developed hypertension but had a normal blood glucose level, identical to that in SD rats as reported previously.16,17 Streptozotocin-induced diabetes mellitus increased blood glucose levels (Table 2). Treatment with ARB or ARNI did not affect the glucose level nor the body weight, but significantly reduced mean arterial blood pressure (Table 2). Streptozotocin-induced diabetic retinopathy in Ren2 rats is
associated with a corresponding increase in the activity of NEP enzyme (Fig. 1). Treatment with ARB and ARNI reduced the level of NEP activity in the 5- and 12-week studies, with ARNI having a stronger effect than ARB in the 5-week study but appear to have almost a similar effect in the 12-week study (Fig. 1B).

**ARNI Reduced Gliosis More Strongly Than ARB After 12 Weeks of Diabetes**

Immunostaining for GFAP, an astrocyte-specific marker, was done in each group to evaluate the level of gliosis. In a normal healthy retina, GFAP expression is confined to the astrocytes at the inner limiting membrane. However, under pathologic conditions, like DR, GFAP expression is elevated and also observed in the Müller cell processes that extend across the retina from the inner limiting membrane to the outer limiting membrane. In a previous study in nondiabetic Ren2 rats, we observed that retinal GFAP expression is slightly elevated versus age-matched SD controls in astrocytes. In diabetic Ren2 rats, retinal GFAP expression was greatly elevated, and seen along the Müller cell processes (Fig. 2). The longer the duration of diabetes, the higher the level of GFAP expression that was observed. Angiotensin receptor blocker- and ARNI-treated groups showed similarly reduced retinal gliosis compared to the vehicle-treated group in the 5-week study. In the 12-week study, the ARNI-treated group showed a marked reduction in the level of GFAP expression when compared to the vehicle and ARB-treated groups (Figs. 2A–D). Retinal sections from each group also were immunostained for Iba-1, which is a marker for activated microglial cells. In the 5-week study, ARB- and ARNI-treated groups displayed almost the same number of Iba-1–positive cells as the vehicle-treated group. In the 12-week study, the total number of Iba-1–positive cells was significantly (*P < 0.01) reduced in the ARNI-treated group when compared to the vehicle and ARB-treated groups (Figs. 3A, 3B). Angiotensin receptor blocker treatment alone also reduced the total number of Iba-1–positive cells versus vehicle.

**ARNI Is More Effective Than ARB in Reducing Apoptotic Cell Death After 12 Weeks of Diabetes**

Paraffin sections from each group were processed for TUNEL labeling to evaluate retinal degeneration. Compared to the nondiabetic control group the diabetic vehicle-treated groups showed a marked increase in the number of cells undergoing apoptotic cell death in the 5-week (2.4-fold increase) and 12-week (2.8-fold increase) study. The ARB- and ARNI-treated groups showed similarly reduced apoptotic cell death com-
pared to the vehicle-treated group in the 5-week study. In the 12-week study, the ARNI-treated group showed a marked reduction (51%) in the number of apoptotic cell deaths when compared to the vehicle-treated group, while the ARB-treated group showed only a 25% reduction versus vehicle (Figs. 4A, 4B). Immunostaining for Brn3a which is a specific retinal ganglion cell (RGC) marker was used to quantify the number of RGC in retinal sections from each experimental group as another measure for retinal neurodegeneration. Number of Brn3a⁺ cells in the control group was significantly higher when compared to the 5-week and 12-week vehicle-treated group. In the 5-week study, ARB and ARNI treatment resulted in a statistically significant increase in number of Brn3a⁺ RGC cells when compared to the vehicle-treated group. In the 12-week study ARNI-treated group showed an increase in number of Brn3a⁺ RGC cells while the ARB and vehicle-treated group showed a reduced Brn3a⁺ RGC cells (Fig. 4C).

**ARNI Reduced Capillary Loss More Strongly Than ARB After 12 Weeks of Diabetes**

We have reported previously that the Ren2 rat retina shows an increased loss of capillaries when compared to age-matched SD rats. Streptozotocin-induced diabetes in Ren2 rats further exacerbated this loss. Angiotensin receptor blocker- and ARNI-treated groups showed a similar reduction in the number of acellular capillaries compared to vehicle-treated group in the 5-week study. In the 12-week study, ARNI treatment showed significantly more reduction in capillary loss (68% vs. 43% reduction) than ARB treatment (Fig. 5).

**ARNI Decreased Expression Levels of Inflammatory Markers More Strongly Than ARB After Both 5 and 12 Weeks of Diabetes**

Real-time RT-PCR was used to evaluate the expression level of inflammatory cytokines and angiogenic factors in the
retina from each experimental group. In the 5-week study and the 12-week study ARB and ARNI treatment significantly reduced the mRNA levels of TNF-α, intercellular adhesion molecule-1 (ICAM-1), VEGF, and monocyte chemoattractant protein-1 (MCP-1) when compared to the vehicle treated groups (Fig. 6).

**DISCUSSION**

The present study first showed that STZ-induced diabetes in Ren2 rats resulted in increased levels of NEP activity, capillary loss, inflammatory cytokine expression, gliosis, and neuronal apoptotic cell death in the retina, which all are indicators of...
DR. This is consistent with our earlier work in this model.17 Secondly, these symptoms exacerbated after a longer duration of diabetes; the increase in capillary loss, inflammatory cytokine expression, gliosis, and apoptotic cell death were all significantly worsened after 12 weeks of diabetes compared to 5 weeks of diabetes. This could have important clinical significance in terms of developing potential therapeutics, as DR, a progressive retinal neurovascular disorder, is strongly associated with prolonged duration of diabetes in patients.1

Thirdly, this study provides strong evidence that, in the 12-week study, ARNI is much more effective than ARB alone in ameliorating the retinal neurovascular dysfunctions observed in diabetic Ren2 rats, while the two treatments were equally effective at 5 weeks. Thus, the use of a NEP inhibitor in addition to an ARB seems to provide additional benefits effects on the retinal neurovascular system, making ARNI a promising therapeutic approach in the treatment of DR. To what degree the beneficial effects of ARNI in the eye at 12 weeks occurred independently of blood pressure still must be investigated. Nevertheless, given the identical blood pressure lowering effects of ARNI and ARB at 5 weeks, at this stage there is no reason to believe that this would be entirely different at 12 weeks.

A large body of evidence suggests that a deficiency in the natriuretic peptide system in addition to a hyperactive RAS is associated with various renal and cardiovascular diseases like heart failure, hypertension, and metabolic syndromes.27–29 Natriuretic peptides are a family of hormones that help maintain sodium and fluid balance. This system comprises three structurally similar peptides: atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and C-type natriuretic peptide (CNP).30 All three peptides have cardiorenal protective properties. Natriuretic peptides, in addition to having potent natriuretic, diuretic, and vasodilator properties, also lower sympathetic drive, and have antiproliferative and anti-hypertrophic effects.31 These actions are mediated by the binding of ANP and BNP to the type A receptor, which is coupled to guanylyl cyclase. C-type natriuretic peptide is found mostly in the central nervous system, kidneys, and vascular endothelial cells; it has antithrombotic and antifibrotic effects and binds to the type B receptor. The activation of both these receptors increases the expression of the second messenger cGMP, which mediates most of the natriuretic peptide mechanisms of action. The natriuretic peptides are cleared from circulation via receptor-mediated internalization (involving the natriuretic peptide clearance receptor) and/or degradation by extracellular proteases, like NEP.52–55 Natriuretic peptides and their receptors are expressed and functional in the rodent and human eyes in lens epithelial cells, vitreous, neural retina, and RPE.54–56 Although their role in the retina is not yet clear, induction of diabetes in rats causes downregulation of retinal ANP expression. The activity level of NEP in the vitreous of patients with proliferative DR is increased compared to control patients.56 Additionally, in our present study we showed that STZ-induced DR in Ren2 rats results in increased level of NEP activity, which can be significantly reduced by ARB and ARNI treatment. Moreover, it has been shown that ANP and CNP can suppress endothelial and RPE leakage, prevent choroidal neovascularization,57,58 and reverse advanced glycation end-product-induced retinal blood-barrier dysfunction in RPE.55 All these processes precede the development of DR. Thus, inhibiting NEP and increasing the level of natriuretic peptides in the retina could be beneficial in the treatment of DR.

Increasing the levels of natriuretic peptide by NEP inhibitors has been investigated as a therapeutic approach for treatment of hypertension and heart failure.59,60 However, the use of NEP inhibitors individually was not very beneficial, due to its broad effects on a variety of substrates other than natriuretic peptides.31 Indeed, NEP is critical for the processing and catabolism of vasoactive peptides and peptides involved in diuresis, natriuresis, and blood pressure regulation, like angiotensin II, bradykinin, substance P, adrenomedullin, glucagon, vasoactive intestinal peptide, and endothelin-1.30 Therefore, in recent studies NEP inhibitors were used in combination with other cardiovascular agents, such as ACEi and ARBs, to at least counteract their potentiating effects on angiotensin II.51,41,42 The combination of a NEP inhibitor and an ACEi was not useful because of a high incidence of angioedema, due to increased bradykinin levels.43,44 related to the fact that NEP and ACE are the main enzymatic pathways for the breakdown of bradykinin. An alternative combination is that of an ARB and a NEP inhibitor (ARNI). Angiotensin receptor blockers do not disrupt bradykinin metabolism, and patients on ARNI did not seem to develop angioedema.41,42 This combination could be additionally beneficial because blockade of the angiotensin II type 1 receptor by ARB facilitates the binding of angiotensin II to the angiotensin II type 2 receptor that elicits several favorable actions. Clinical studies using ARNI for the treatment of heart failure and hypertension have shown much stronger favorable results when compared to ARB, without any extra associated negative side effects.10,12,42,45

Possible chronic adverse effects of NEP inhibitors on the eye have not specifically been assessed yet. Neprilysin has a possible neuroprotective effect as it brings about degradation of the amyloid β peptide.56,66 Elevated levels of amyloid β peptide in the brain is associated with cognitive impairment, and extracellular deposition leads to the development of Alzheimer’s disease. Elevated levels of amyloid β peptide in the eye have been found in different progressive retinal neurodegenerative disorders, such as age-related macular degeneration.47–49 Hence, further studies must be done to better understand the long-term effects of NEP inhibitors on the eye before they can be applied for the treatment of DR. Nevertheless, the beneficial effect that ARNI has over ARB on retinal neurovascular symptoms in diabetic Ren2 rats suggest that this treatment holds promise as a novel potential therapeutic strategy for treatment of patients with DR.

Acknowledgments

Supported in part by NIH Grants EY021752, EY024564, American Diabetes Association, and Bright Focus Foundation (QL). Core facilities were supported by NEI grant P30 EY02177 and Research to Prevent Blindness to University of Florida.

Disclosure: T. Prasad, None; L.C.W. Roksnoer, None; P. Zhu, None; A. Verma, None; Y. Li, None; W.W. Batenburg, None; R. de Vries, None; A.H.J. Danser, None; Q. Li, None

References

1. Wong TY, Cheung CM, Larsen M, Sharma S, Simo R. Diabetic retinopathy. *Nat Rev Dis Primers*. 2016;2:16012.
2. Estacio RO, McFarling E, Biggerstaff S, Jeffers BW, Johnson D, Schrier RW. Overt albuminuria predicts diabetic retinopathy in Hispanics with NIDDM. *Am J Kidney Dis*. 1998;31:947–953.
3. Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. *Trends Endocr Metab*. 2005;16:120–126.
4. Cohn JN. Role of the renin-angiotensin system in cardiovascular disease. *Cardiovasc Drugs Ther*. 2010;24:341–344.
5. Ghattach A, Lip PL, Lip GY. Renin-angiotensin blockade in diabetic retinopathy. *Int J Clin Pract*. 2011;65:113–116.
ARNI Protects Against Diabetic Retinopathy

6. Fletcher EL, Phipps JA, Ward MM, Vessey KA, Wilkinson-Berka JL. The renin-angiotensin system in retinal health and disease: Its influence on neurons, glia and the vasculature. *Prog Retin Eye Res* 2010;29:284–311.

7. Hanes DS, Nahar A, Weir MR. The tissue renin-angiotensin-aldosterone system in diabetes mellitus. *Curr Hyperten Rep* 2004;6:98–105.

8. Mauer M, Zimman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. *N Engl J Med*. 2009;361:40–51.

9. Seymour AA, Norman JA, Asaad MM, et al. Antihypertensive and renal activity of SQ 28,603, an inhibitor of neutral endopeptidase. *J Cardiovasc Pharmacol*. 1999;17:296–304.

10. Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: in a randomised, double-blind, placebo-controlled, active comparator study. *Lancet*. 2010;375:1255–1266.

11. McMurray JJ, O'Connor C. Lessons from the TOPCAT trial. *New Engl J Med*. 2014;370:1453–1454.

12. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *New Engl J Med*. 2014;371:993–1004.

13. McMurray JJ, Packer M, Solomon SD. Neprilysin inhibition for heart failure. *New Engl J Med*. 2014;371:2336–2337.

14. Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. *Lancet*. 2012;380:2129–2143.

15. Salomon JA, Wang H, Freeman MK, et al. Healthy life expectancy for 187 countries, 1990–2010: a systematic analysis for the global burden of disease study 2010. *Lancet*. 2012;380:2144–2162.

16. Roksnoer LCW, van Veghel R, Claar D, van Groningen MC, et al. Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptor-neprilysin inhibition versus AT1 receptor blockade alone. *Clin Sci (Lond)*. 2016;130:1209–1220.

17. Batenburg WW, Verma A, Wang Y, et al. Combined renin inhibition/(pro)renin receptor blockade in diabetic retinopathy—a study in transgenic (mREN2)27 rats. *Plos One* 2014;9:e100954.

18. Kelly DJ, Wilkinson-Berka JL, Allen TJ, Cooper ME, Skinner SL. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mREN-2)27 rat (TGR). *Kidney Int*. 1998;54:343–352.

19. Moravski C, Skinner SL, Stubbs AJ, et al. The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies. *Am J Pathol*. 2003;162:151–160.

20. Wilkinson-Berka JL, Tan G, Binger KJ, et al. Aliskiren reduces vascular pathology in diabetic retinopathy and oxygen-induced retinopathy in the transgenic (mREN-2)27 rat. *Diabetologia*. 2011;54:2724–2735.

21. Roksnoer LCW, van Veghel R, de Vries R, et al. Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats. *Kidney Int*. 2015;88:109–120.

22. Johnson MS, DeMarco VG, Heesch CM, et al. Sex differences in baroreflex sensitivity, heart rate variability, and end organ damage in the TGR(mRen2)27 rat. *Am J Physiol Heart Circ Physiol*. 2011;301:H1540–1550.

23. van Esch JHM, Moltzer E, van Veghel R, et al. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats. *J Hypertens*. 2010;28:21–2155.

24. Katsuda T, Tsuchiya R, Kosaka N, et al. Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes. *Sci Rep*. 2013;3:1197.

25. Miners JS, Verbeek MM, Rikkert MO, Kehoe PG, Love S. Immunonucapture-based fluorometric assay for the measurement of neprilysin-specific enzyme activity in brain tissue homogenates and cerebrospinal fluid. *J Neurosci Methods*. 2008;167:229–236.

26. Li Q, Verma A, Han PY, et al. Diabetic eNOS knock-out mice develop accelerated retinopathy. *Invest Ophthalmol Vis Sci*. 2010;51:5240–5246.

27. Belluardo P, Cataliotti A, Bonaiuto L, et al. Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy. *Am J Physiol Heart Circ Physiol*. 2006;291:H1529–H1535.

28. Machetet F, Heublein D, Costello-Boerrigter LC, et al. Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP. *J Am Coll Cardiol*. 2012;60:1558–1565.

29. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. *Circulation*. 2004;109:594–600.

30. Daniels LB, Maisel AS. Natriuretic peptides. *J Am Coll Cardiol*. 2007;50:2357–2368.

31. Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC Jr. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. *Eur Heart J*. 2013;34:886–893c.

32. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. *Endocr Rev*. 2006;27:47–72.

33. Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. *Handb Exp Pharma- col*. 2009;341:366–396.

34. Cammarata PR, Braun B, Dimitrijevich SD, Pack J. Characterization and functional expression of the natriuretic peptide system in human lens epithelial cells. *Mol Vis*. 2010;16:630–638.

35. Dahrour M, Alsarraf O, Liu Y, Crosson CE, Ablonczy Z. C-type natriuretic peptide protects the retinal pigment epithelium against advanced glycation end-product-induced barrier dysfunction. *J Pharmacol Exp Ther*. 2013;344:96–102.

36. Hara H, Oh-hashi K, Yoneda S, et al. Elevated neprilysin activity in vitro and patients with proliferative diabetic retinopathy. *Mol Vis*. 2006;12:977–982.

37. Lara-Castillo N, Zandi S, Nakao S, et al. Atrial natriuretic peptide reduces vascular leakage and choroidal neovascularization. *Am J Pathol*. 2009;175:2343–2350.

38. Xing J, Moldobaeva N, Birukova AA. Atrial natriuretic peptide protects against Staphylococcus aureus-induced lung injury and endothelial barrier dysfunction. *J Appl Physiol*. 2011;110:213–224.

39. Cleland JG, Swedberg K. Lack of efficacy of neutral endopeptidase inhibitor ecatodril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators. *Lancet*. 1998;351:1657–1658.

40. Martin FL, Stevens TL, Cataliotti A, et al. Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure. *Kidney Int*. 2005;67:1723–1730.

41. Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. *JACC Heart Fail*. 2014;2:663–670.

42. Tummala R, Bhadra R, Gupta A, Ghosh RK. Combined neprilysin and RAS inhibition in cardiovascular diseases: a review of clinical studies. *J Cardiovasc Pharmacol*. 2016;68:183–190.

43. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the
Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. *Am J Hypertens*. 2004;17:103–111.

44. Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. *Lancet*. 2000;356:608–609.

45. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. *Lancet*. 2012;380:1387–1395.

46. Iwata N, Tsubuki S, Takaki Y, et al. Metabolic regulation of brain Aβ by neprilysin. *Science*. 2001;292:1550–1552.

47. Ding JD, Johnson LV, Herrmann R, et al. Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. *Proc Natl Acad Sci U S A*. 2011;108:E279–E287.

48. Ning A, Cui J, To E, Ashe KH, Matsubara J. Amyloid-beta deposits lead to retinal degeneration in a mouse model of Alzheimer disease. *Invest Ophthalmol Vis Sci*. 2008;49:5136–5143.

49. Yoshida T, Ohno-Matsui K, Ichinose S, et al. The potential role of amyloid beta in the pathogenesis of age-related macular degeneration. *J Clin Invest*. 2005;115:2793–2800.